Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently filed three new patents (https://ibn.fm/wWksA). The patent applications seek protection for innovative combination therapies involving buntanetap that improve cognition beyond normal levels.
Specifically, the patent filings cover buntanetap combined with a glucagon-like peptide-1 (“GLP-1”) agonist, buntanetap combined with a phosphodiesterase 5 (“PDE5”) inhibitor, and a combination of all three. According to the company, these combinations create a multi-sided approach to treating neurodegenerative diseases.
The motivation to seek patent protection stems from the successes of recent preclinical studies, which have provided compelling results that demonstrate the strong potential for the combinations to enhance cognition. Data from these studies have shown that buntanetap combined with PDE5 inhibitors or GLP-1 agonists improves cognitive function in Alzheimer’s mouse models beyond levels observed in healthy controls.
Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis, noted, “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement.” Maria went on to state that the combination of buntanetap with Trulicity and Viagra has the potential to “restore cognition to healthy levels” and improve it “beyond normal level, offering new hope in the fight against dementia.”
According to an August 6 news release, buntanetap significantly amplifies the effects of Trulicity on memory and learning, leading to a “6- to 10-fold increase in efficacy,” according to Maria. The company observes that this synergy helps enhance treatment outcomes while simultaneously lessening potential side effects (https://ibn.fm/0zRY1).
Buntanetap targets neurodegeneration by inhibiting the production of various neurotoxic proteins, including TDP43, alpha-synuclein, tau, and amyloid beta. It improves the affected function in neurodegenerative diseases, enhances cognition in early AD patients, improves motor function and stops cognitive decline in PD patients.
The company’s recent Phase 2/3 study of buntanetap in patients with early (mild to moderate) AD showed a statistically significant improvement in cognition. The Phase 2/3 study gave the company valuable information for a planned Phase 3 pivotal trial (https://ibn.fm/sVv02). In addition, the company has separately completed a Phase 3 study of buntanetap in patients with early PD (https://ibn.fm/FIM3D).
“Since buntanetap has completed Phase 3 studies as a standalone treatment, and a number of GLP-1 agonists and PDE5 inhibitors are FDA-approved, these combinations are well positioned for Phase 3 human trials,” expressed Maria in the Sept. 30 news release announcing the patent filings.
The new patent applications are expected to further strengthen the company’s expansive intellectual property portfolio. Annovis currently has more than 35 total issued patents, plus plenty more pending applications in various jurisdictions, according to its latest Form 10-K filing (https://ibn.fm/YzxJB).
The issued patents and pending applications speak to the company’s resolve to “protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties,” as a source of its unique value to shareholders and competitive advantage.
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused…
Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The…
Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio…
The FIFA World Cup started on June 11 and will end on July 19. 48…
A study conducted by a team at Mass General Brigham has found that people with…